Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure
2024-03-21
临床2期免疫疗法临床1期
Plus, news about Evommune, Maruho and Nouscom:
Innate Pharma gives up on Phase 1b trial for cancer drug:
The company was evaluating lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphomaKIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma. Innate said it’s
not planning
to restart recruitment in the trial after a
clinical hold
was put into place for studies assessing the drug in PTCL and cutaneous T cell lymphoma after a patient death was reported in the latter. It cited a lack of “meaningful clinical activity” for lacutamab in the PTCL study evaluating the drug as a monotherapy. It is still being studied in combination with chemo in a Phase 2 trial in PTCL.
— Katherine Lewin
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。